The claims made in the post by the basher frrol are

New Post Public Reply Private Reply Replies (0) Message Board
Drano
404
The claims made in the post by the basher frrol are deceptive and untrue. Uceris is not the primary drug used for treatment for Ulcerative Colitis. Uceris can have significant side effects. And, claiming the sales figures for Uceris have any relevance to the potential sales for Brilacidin is utterly wrong.

Uceris is a steroid. According to the company's website,
Quote:
UCERIS tablets may reduce the level of flare-ups in the colon, which helps the lining of the colon to heal.

Meanwhile, in a short course of treatment, Brilacidin healed the lesions -- as shown by the gold standard of evidence, photographic proof of before-and-after healing (via sigmoidoscopy). We do not know yet if it is a cure, or merely causes a long-lasting remission -- but it actively heals, and in a shorter course of NON-SYSTEMIC treatment -- Brilacidin 42 days, Uceris 56 days.

Brilacidin has seemingly no significant side effects, as it is not systemically absorbed. What about Uceris? According to the company,
Quote:
UCERIS tablets may weaken your immune system. Taking medicines that weaken your immune system makes you more likely to get infections.
....some people may have too much corticosteroid medicine in their blood (hypercorticism). Talk to your doctor if you have any symptoms of hypercorticism, including: acne, bruising easily, rounding of your face (moon face), ankle swelling, thicker or more hair on your body and face, a fatty pad or hump between your shoulders (buffalo hump), or pink or purple stretch marks on the skin of your abdomen, thighs, breasts, and arms.


It is incredibly deceptive to cherry-pick ONE drug -- Uceris -- out of the vast numbers of drugs used for ulcerative colitis, and then claim that the market for ALL UC drugs is small, because one drug is not used very much.
This is like claiming the market for Bayer-brand aspirin is the entire market for over-the-counter pain relief - - not including Tylenol or any of the NSAIDS like Ibuprofen or Naproxen -- and all of their generics. Contrary to the deceptive post, Uceris is very, very far from being "the go-to drug" for this syndrome.

Drugs used include (broad categories):
Quote:
•5-aminosalicylic acid (5-ASA). Balsalazide, mesalamine, olsalazine, and sulfasalazine are the main medications used to treat ulcerative colitis....
Corticosteroids. [Note: this category includes Uceris as one of many drugs]
•These anti-inflammatory drugs can be used if 5-ASA drugs don't work for you or if you have more severe disease. These medicines sometimes have side effects and long-term complications....
•Immunosuppressants. If corticosteroids or 5-ASA drugs don't help, your doctor may prescribe these kinds of drugs....
•Biologics. This group of drugs includes adalimumab (Humira), adalimumab-atto (Amjevita) and adalimumab-adbm (Cyltezo) - biosimilars to Humira, certolizumab pegol (Cimzia), golimumab (Simponi, SImponi Aria), infliximab (Remicade), ), Infliximab-abda (Renflexis), infliximab-dyyb (Inflectra), a biosimilar to Remicade, tofacitinib (Xeljanz), and vedolizumab (Entyvio).
https://www.webmd.com/ibd-crohns-disease/ulce...-colitis#2



Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 7

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
Machine Grabs Prime Dallas Property Amid Apartment Boom

Updated Category News Views 4

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 5

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 7

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 6

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading

Top 5 Most Recently Viewed Articles

Ascendis Pharma Reports Q2 2024 Results and Positive Outlook

Updated Category News Views 78

Ascendis Pharma Reports Mixed Q2 Results Ascendis Pharma A/S (NASDAQ: ASND) has unveiled its financial results for the second quarter of 2024, revealing a mix of achievements and hurdles. A significant highlight of this quarter was the U.S. approval of YORVIPATH for the treatment of adult hypoparathyroidism. This marks a major milestone as it represents the company's...

Continue Reading
Analyzing New Zealand's Economic Growth and Monetary Policy Shifts

Updated Category News Views 135

New Zealand’s Economic Growth Overview New Zealand's latest growth figures present a significant turning point for a nation that has been adjusting to the impacts of substantial monetary easing. The economy showed a quarterly expansion of 1.1%, bouncing back after a contraction of 1.0% previously. This growth not only exceeded expectations, which were around 0.9%, but...

Continue Reading
Eli Lilly's Competitive Landscape in the Pharmaceuticals Sector

Updated Category News Views 688

Exploring Eli Lilly's Impact on the Pharmaceuticals Sector In the dynamic and competitive world of pharmaceuticals, understanding the role of companies like Eli Lilly & Co. (NYSE: LLY) is crucial for investors and stakeholders alike. This article offers a detailed comparative analysis of Eli Lilly's performance against its main competitors, focusing on key financial...

Continue Reading
Veriff Welcomes Tech Visionary Ott Kaukver to Its Board

Updated Category News Views 165

Veriff Expands Its Board with Industry Expertise Veriff, an innovative identity verification company known for its AI-native technology, recently appointed Ott Kaukver to its Board of Directors. This significant move illustrates the company’s determination to enhance trust in online identities globally. Kaukver, recognized for his role as the former CTO of Twilio and...

Continue Reading
University of Phoenix's New Initiative Promotes Responsible AI Use

Updated Category News Views 154

University of Phoenix Launches Center for AI Resources University of Phoenix has taken a significant step towards empowering its students and faculty by launching the Center for AI Resources. This initiative is designed to equip learners with essential knowledge for navigating the increasingly complex landscape of generative AI (GenAI). The Center serves as a...

Continue Reading